Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older
- Women's Cancer Research Foundation
- Oct 5, 2022
- 1 min read
Updated: Jan 12, 2024
Currently, there are few modifiable risk factors associated with ovarian cancer. However, preclinical studies suggest that bisphosphonates (medicine that prevents bone loss and strengthens bones) could have chemo-preventive (the use of drugs to reduce the risk of cancer) effects.
In a recent study, researchers sought to assess the association between use of bisphosphonates and the risk of epithelial ovarian cancer. From July 2002 and December 2013, women with epithelial ovarian cancer diagnosed at age 50 years were randomly selected based upon demographic factors and use of bisphosphonates or other osteoporosis medicines. Every use of bisphosphonates was associated with a reduced risk of epithelial ovarian cancer compared with no use.
In conclusion, bisphosphonates were associated with a reduced risk of ovarian cancer, suggesting that this medication should be considered for further evaluation as a preventative measure in reducing the risk of ovarian cancer.
More Ovarian Cancer Information:
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media:
Comments